BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Doctors Test Advanced Envisioneering Medical Technologies's TargetScan Tool for Treating Prostate Cancer


10/27/2008 3:25:33 PM

St. Louis, Mo. (October 27, 2008) – Leading radiation oncologists are using the TargetScan Touch™ system to deliver radioactive seed therapy in the prostate. The innovative technology is based on a motionless probe which stabilizes the prostate during procedures. With the gland stabilized, physicians use a touch-screen interface and 3-D ultrasound images to map and confirm placement of radiation.

Unveiled recently at the 2008 American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting, the TargetScan Touch™ has been tested at several of the nation’s leading medical centers, including Emory University School of Medicine.

“This technology delivers two important benefits. First, a stabilized prostate; second, the ability to quickly and efficiently image anywhere in the prostate with the point and click function for accurate positioning of radioactivity,” explains Peter Rossi, M.D., Emory’s assistant professor in the departments of radiation oncology and urology. “TargetScan has a short learning curve for my residents and physicists and has demonstrated its value in that we have consistently achieved quality implants with its help.”

Just launched, the system will initially be in clinical use at Emory, Washington University Medical Center in St. Louis, University of Florida and New Hanover Radiation Oncology. The system is based on the TargetScan® technology platform developed by Envisioneering Medical Technologies in St. Louis, under the guidance of physicians at Washington University. “Traditional hand-manipulated devices allow the prostate gland to shift, which impedes placement accuracy. By stabilizing the prostate, physicians can now implant seeds to any and every region of the gland with greater confidence,” said Robert Mills, president, Envisioneering Medical Technologies

Other system features include intuitive imaging and navigational controls and a compact, streamlined system design to enhance treatment efficiency, improve the patient experience and provide ease of transport for physicians managing multiple practice locations.

“The design of TargetScan Touch™ is straightforward to support ease of use and widespread adoption so that physicians and their patients can benefit from this new technology,” added Mills. “The simplicity of the touch-screen technology saves time while producing detailed images and treatment reports for future patient monitoring.” TargetScan Touch Technical Features:

• Motionless probe to prevent prostate movement and on-screen image distortion..

• Mapping technology for complete prostatic coverage, assisting with accurate needle placement to pre-planned cancer targets and preferred treatment zones.

• 3-D image acquisition to improve visibility, presenting both sagittal and transverse planes with a total viewing volume of 380 mL.

• Touch-screen technology to improve treatment efficiency and patient experience.

. About Envisioneering Medical Technologies

Envisioneering Medical Technologies, based in St. Louis, Mo., is dedicated to creating the standard for prostate cancer care by developing technology for improving prostate cancer diagnosis and treatment precision and effectively managing patients throughout the continuum of care. For more information please visit www.envisioneeringmedical.com.

Reporter’s Note:

• High-resolution, electronic images of the TargetScan Touch device are available.

• We can coordinate interviews with TargetScan Touch developers and physicians, like Dr. Peter Rossi, who have used this system in a clinical setting.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->